# US 2017/0304405 A1 · Treatment of hormonal disorders of growth

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0304405 A1
- Document ID: US20170304405A1
- Status: Published application
- Kind: A1
- Application number: 15/525,928
- Filed: 2015-11-12
- Published: 2017-10-26
- Earliest claimed: 2014-11-12
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human; Universite De Liege; Centre Hospitalier Universitaire De Liege
- Applicants: The United States of America, as represented by the Secretary, Department of Health and Human; Universite De Liege; Centre Hospitalier Universitaire De Liege
- Inventors: Albert Beckers; Adrian Francis Daly; Fabio Rueda Faucz; Constantine A. Stratakis; Giampaolo Trivellin
- Web page: https://patentgrep.com/patent/US20170304405A1

## CPC

- A61K 38/31: Somatostatins
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 31/48: Ergoline derivatives, e.g. lysergic acid, ergotamine
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 38/1709: {from mammals}
- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 5/06: of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P 35/00: Antineoplastic agents
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/723: {G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention refers to a GPR101 inhibitor, antagonist or inverse agonist or inverse agonist for use in preventive and/or therapeutic treatment of diseases selected from the group consisting of acromegaly and gigantism and to methods for preventive and/or therapeutic treatment of diseases selected from the group consisting of acromegaly and gigantism wherein to a subject GPR101 inhibitor, antagonist or inverse agonist is administered. Further, the present invention provides a GPR101 agonist for use in preventive and/or therapeutic treatment of disorders selected from the group consisting of dwarfism, short stature, hypopituitarism and a disease of low levels of pituitary hormone secretion and to methods for preventive and/or therapeutic treatment of diseases selected from the group consisting of dwarfism, short stature, hypopituitarism and a disease of low levels of pituitary hormone secretion wherein to a subject GPR101 agonist is administered. The present invention also provides GHRH inhibitors, antagonists or inverse agonists and GH antagonists for use in the therapeutic treatment of X-linked acrogigantism (X-LAG syndrome). In addition, the present invention refers to a method of increasing body mass and/or body size of livestock comprising administering to livestock an effective amount of GPR101 agonist. Further, the present invention is directed to a non-human transgenic animal, comprising as expressed transgene a gene encoding GPR101 or overexpressing endogenous GPR101 gene.

## Claims

### Claim at position 1

1-14. (canceled)

### Claim 15

A method for reducing hormone secretion from the hypothalamus and pituitary gland in a subject comprising administering to the subject an effective amount of a GPR101 antagonist, thereby reducing hormone secretion from the hypothalamus and pituitary gland in the subject.

### Claim 16

A method for reducing hormone production by a pituitary tumor or hyperplasia in a subject, comprising administering to the subject an effective amount of a GPR101 antagonist, thereby reducing hormone production by the pituitary tumor or hyperplasia in the subject.

### Claim 17 (depends on 16)

The method of claim 16, wherein the method reduces the growth velocity of the subject with the pituitary tumor or hyperplasia, where said tumor or hyperplasia causes growth hormone over-secretion and increased height, by administering a GPR101 antagonist.

### Claim 18

A method for reducing hormone production by a pituitary tumor or hyperplasia in a subject with a tumor or hyperplasia that over-secretes growth hormone, wherein said over-secretion leads to the clinical disease of acromegaly, comprising administering a GPR101 antagonist to the subject, thereby reducing hormone production by the pituitary tumor or hyperplasia.

### Claim 19

A method for reducing hormone production by a pituitary tumor or hyperplasia in a subject, comprising administering to the subject an effective amount of a GRP101 antagonist, where said tumor or hyperplasia over-secretes prolactin, is an adrenocorticotropic hormone (ACTH) secreting pituitary tumor that causes Cushing's disease, is a thyroid stimulating hormone (TSH) secreting pituitary adenoma, or is a pituitary tumor secreting a variety of different hormones.

### Claim 20

A method for controlling the growth of a pituitary tumor in a subject, comprising administering to the subject an effective amount of a GPR101 antagonist, thereby controlling the growth of the pituitary tumor, where the tumor secretes functional hormone or no functional hormones.

### Claim 21

A method for increasing hormone production from the hypothalamus and pituitary gland in a subject, comprising administering to the subject an effective amount of a GPR101 agonist, or a GPR101 protein, thereby increasing hormone production from the hypothalamus and pituitary gland.

### Claim 22 (depends on 21)

The method of claim 21, wherein said subject has the disease of hypopituitarism and low levels of pituitary hormone secretion.

### Claim 23 (depends on 21)

The method of claim 21, wherein said subject has the disease of dwarfism or short stature due to growth hormone deficiency.

### Claim 24 (depends on 23)

The method of claim 23, wherein the method increases the growth velocity of the subject.

### Claim 25 (depends on 15)

The method according to claim 15 wherein the said subject is a human.

### Claim 26 (depends on 15)

The method according to claim 15 wherein the said subject is a non-human animal.

### Claim 27

A method of treating a subject with X-linked acrogigantism, comprising administering the subject an effective amount of a growth hormone releasing hormone (GHRH) inhibitor, antagonist or inverse agonist, thereby treating the X-linked acrogigantism in the subject.

### Claim 28 (depends on 27)

The method according to claim 27, wherein the X-linked acrogigantism is characterized by gigantism occurring during infancy and a microduplication in chromosome Xq26.3 that comprises the orphan G-protein coupled receptor (GPCR) gene, GPR101.

### Claim 29 (depends on 27)

The method according to claim 27, wherein the GHRH inhibitor, antagonist or inverse agonist is selected from the group consisting of pasireotide, octreotide, lanreotide, cabergoline, and hGHRH peptide antagonist.

### Claim 30

A method for treating a subject with X-linked acrogigantism, comprising administering to the subject an effective amount of a growth hormone (GH) antagonist, thereby treating the X-linked acrogigantism in the subject.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the X-linked acrogigantism is characterized by gigantism occurring during infancy and a microduplication in chromosome Xq26.3 that includes the orphan G-protein coupled receptor (GPCR) gene, GPR101.

### Claim 32 (depends on 30)

The method according to claim 30, wherein the GH antagonist is pegvisomant.

### Claim 33

A method of increasing body mass and/or body size of livestock comprising administering to livestock an effective amount of GPR101 agonist, or a GPR01 protein, thereby increasing body mass and/or body size of the livestock.

### Claim 34

(canceled)

### Claim 35

A non-human transgenic mammal, expressing a transgene encoding GPR101 or overexpressing endogenous GPR101 gene.

### Claim 36 (depends on 35)

The non-human transgenic animal according to claim 35, wherein the transgene comprises the nucleic acid sequence shown in SEQ ID NO: 1, or encodes a protein having the amino acid sequence shown in SEQ ID NO: 2.

### Claim at position 24

37-38. (canceled)
